MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. today announced that an in-person meeting was held with the U.S. Food and Drug Administration's (FDA) Center for Devices and Radiological Health to discuss FDA's response to MagForce's NanoTherm(TM) Prostate Cancer Therapy Pre-Submission of November, 2014.
Therapeutic oligonucleotide analogs represent a new and promising family of drugs that act on nucleic acid targets such as RNA or DNA; however, their effectiveness has been limited due to difficulty crossing the cell membrane.
Three of the four most fatal cancers are caused by a protein known as Ras; either because it mutates or simply because it ends up in the wrong place at the wrong time. Ras has proven an elusive target for scientist trying to cure the deadly diseases. Now a group from the Department of Chemistry, University of Copenhagen have discovered an unknown way for RAS to find its proper place in the cell. Their discovery may lead to completely novel approaches to curing cancer.
A study led by the National University of Singapore (NUS) found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it has entered into an amendment of its existing credit facility from Hercules Technology III, L.P., an affiliate of Hercules Technology Growth Capital. Under the amendment, the company borrowed an additional $15 million in growth capital, less the repayment of the outstanding balance on BIND’s existing term loan facility of approximately $3 million.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
NanoViricides, Inc. (the "Company"), a nanomedicine company developing anti-viral drugs, reported a good safety profile of an optimized FluCide® drug candidate in a GLP-like toxicology study in rats. These results are extremely important since they indicate that FluCide continues to look very promising as one of the most advanced candidates in the Company's drug development pipeline.
NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reported that it has shipped several anti-Ebola nanoviricide® drug candidates to a hi-security bio-containment facility in the US that is capable of performing evaluation of these drug candidates in the required biological safety level 4 (BSL-4) environment.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced the publication of an article in the Journal of the American Medical Association (JAMA) co-authored by Robert S. Langer, Sc.D, David H. Koch Institute Professor, Massachusetts Institute of Technology, co-founder and member of the Board of Directors of BIND and one of seven individuals to have received both the United States National Medal of Science and the United States National Medal of Technology and Innovation.
Nanomedicine has been developing rapidly in recent years, particularly in the development of novel nano tools for medical diagnosis and treatment. For instance, a new trend is becoming prevalent in developing nanosystems for simultaneous tumor diagnosis and therapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.